BIORESTORATIVE THERAPIES, INC.: 10-Q filed 2021-03-29
What BIORESTORATIVE THERAPIES, INC. reported in its quarterly report filed 2021-03-29 (fiscal Q1 2020): 30 published measures, 58 facts as tagged in accession 0001493152-21-006978.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2021-03-29
- Fiscal period
- fiscal Q1 2020
- Accession
- 0001493152-21-006978 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BIORESTORATIVE THERAPIES, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 1,377,685 | USD | |
| At 2019-12-31 | 1,466,323 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 18,913,790 | USD | |
| At 2019-12-31 | 14,242,469 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | -17,536,105 | USD | |
| At 2019-12-31 | -12,776,146 | USD | |
| At 2019-03-31 | -7,652,744 | USD | |
| At 2018-12-31 | -8,641,038 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | -7,550,772 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -3,883,172 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | -448,646 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -1,980,162 | USD | 90 |
Contract revenue excluding tax
Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 26,000 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 29,000 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 451,762 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 2,358,918 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | -86,120,918 | USD | |
| At 2019-12-31 | -78,570,146 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 43,361 | USD | |
| At 2019-12-31 | 68,402 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 221,881 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 785,678 | USD | 90 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | -818,989 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -2,328,336 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 53,001 | USD | |
| At 2019-12-31 | 68,863 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 18,416,076 | USD | |
| At 2019-12-31 | 13,720,579 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 2,048,776 | USD | |
| At 2019-12-31 | 1,954,427 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 26,000 | USD | |
| At 2019-12-31 | 32,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 844,989 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 2,357,336 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 186,328 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 455,006 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 1,594,651,383 | shares | |
| At 2019-12-31 | 77,851,633 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 68,425,346 | USD | |
| At 2019-12-31 | 65,786,213 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 560,883 | USD | |
| At 2019-12-31 | 589,894 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 586,936 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 720,440 | USD | |
| At 2019-12-31 | 739,164 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 2,918,550 | USD | |
| At 2019-12-31 | 2,921,164 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 602,641 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 1,286,759 | USD | 90 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 43,764 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 52,663 | USD | 90 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | -6,731,783 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -1,554,836 | USD | 90 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | 126,169 | USD | 90 |
Operating lease payments
Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 38,437 | USD | 91 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | -6,000 | USD | 91 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 94,349 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -289,771 | USD | 90 |
Inspect the source
- Entity
- BIORESTORATIVE THERAPIES, INC. / CIK 0001505497
- Captured
- 2026-09-19T11:18:28.483Z
- SEC response SHA-256
fd60c78bee3335eafd56c883fed2689ce9a2b29ba609bffc874788f5f89f9708
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001505497.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))